The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Health and Human Services Secretary Robert F. Kennedy Jr said that President Donald Trump calls him up “three or four times a week” to hound him with the same question. At such a critical moment in US ...

With approximately 60% of prescription drugs coming from Europe, including major brands like Ozempic, Botox and Eliquis, many ...

U.S.-listed shares of Novo Nordisk (NVO) rose 0.5% in early premarket trading Wednesday after the Danish drugmaker reported ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Medicare Advantage usage trends reveal slight declines in 2023, highlighting critical insights for policymakers amid rising ...

The Londonderry Township board of supervisors has postponed the decision on changing zoning rules to allow an AI data center ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

These tariffs would drastically undermine the price advantage Indian drug makers currently enjoy in the US, especially in ...

Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...